TW200300078A - Method of treating disorder related to high cholesterol concentration - Google Patents

Method of treating disorder related to high cholesterol concentration Download PDF

Info

Publication number
TW200300078A
TW200300078A TW091132850A TW91132850A TW200300078A TW 200300078 A TW200300078 A TW 200300078A TW 091132850 A TW091132850 A TW 091132850A TW 91132850 A TW91132850 A TW 91132850A TW 200300078 A TW200300078 A TW 200300078A
Authority
TW
Taiwan
Prior art keywords
item
patent application
scope
compound
composition
Prior art date
Application number
TW091132850A
Other languages
English (en)
Chinese (zh)
Inventor
Shutsung Liao
Ching Song
Original Assignee
Univ Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chicago filed Critical Univ Chicago
Publication of TW200300078A publication Critical patent/TW200300078A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
TW091132850A 2001-11-08 2002-11-08 Method of treating disorder related to high cholesterol concentration TW200300078A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34802001P 2001-11-08 2001-11-08

Publications (1)

Publication Number Publication Date
TW200300078A true TW200300078A (en) 2003-05-16

Family

ID=23366328

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091132850A TW200300078A (en) 2001-11-08 2002-11-08 Method of treating disorder related to high cholesterol concentration

Country Status (5)

Country Link
EP (1) EP1450816A4 (enExample)
JP (1) JP2005508368A (enExample)
CA (1) CA2466033A1 (enExample)
TW (1) TW200300078A (enExample)
WO (1) WO2003039480A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078396B2 (en) 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
TW200619191A (en) 2004-10-27 2006-06-16 Sankyo Co Phenyl compounds with more than 2 substitutes
EP2091926B1 (en) 2006-11-13 2015-10-21 Novartis AG Substituted pyrazole and triazole compounds as ksp inhibitors
US8829213B2 (en) 2009-07-29 2014-09-09 The University Of Chicago Liver X receptor agonists
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
CA2848212C (en) 2011-09-08 2022-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
PT2968369T (pt) 2013-03-13 2018-12-05 Sage Therapeutics Inc Esteroides neuroativos e métodos para o seu uso
CN119269811A (zh) * 2013-03-13 2025-01-07 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
JP2016193835A (ja) * 2013-09-04 2016-11-17 学校法人常翔学園 核内受容体肝臓x受容体アゴニスト
HRP20220112T1 (hr) 2013-12-24 2022-04-15 Virginia Commonwealth University Upotreba oksidacijskog sulfata kolesterola (ocs) za liječenje akutne insuficijencije jetre
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HUE071964T2 (hu) 2015-07-06 2025-10-28 Sage Therapeutics Inc Oxiszterolok és alkalmazási eljárásaik
CA2991311C (en) 2015-07-06 2025-05-06 Sage Therapeutics, Inc. OXYSTEROLS AND THEIR METHODS OF USE
EP3828194B1 (en) 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
SMT202200300T1 (it) 2016-04-01 2022-09-14 Sage Therapeutics Inc Ossisteroli e relativi metodi d'uso
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2884071T3 (es) 2016-07-07 2021-12-10 Sage Therapeutics Inc 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
EP3494125B1 (en) 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
ES2935057T3 (es) 2016-09-30 2023-03-01 Sage Therapeutics Inc C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
RU2019115113A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
KR20230051723A (ko) 2016-10-18 2023-04-18 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4976857A (enExample) * 1972-12-06 1974-07-24
US3963765A (en) * 1973-04-01 1976-06-15 Yehuda Mazur Preparation of derivatives of cholesterol
US4217288A (en) * 1977-03-24 1980-08-12 Wisconsin Alumni Research Foundation Anti-vitamin D compounds
JPS61254599A (ja) * 1985-05-07 1986-11-12 Sumitomo Pharmaceut Co Ltd コレステロ−ルのフツ素誘導体
IL105050A0 (en) * 1992-03-27 1993-07-08 Lilly Co Eli Steroid derivatives
IT1255241B (it) * 1992-07-22 1995-10-20 Simos Contos Derivato di acido biliare e suo uso in terapia
CN1187364C (zh) * 1999-04-30 2005-02-02 亚其发展公司 类固醇衍生物
JP4309661B2 (ja) * 2001-05-03 2009-08-05 ザ ユニバーシティー オブ シカゴ 肝臓x受容体

Also Published As

Publication number Publication date
WO2003039480A2 (en) 2003-05-15
CA2466033A1 (en) 2003-05-15
EP1450816A2 (en) 2004-09-01
WO2003039480A3 (en) 2003-06-19
JP2005508368A (ja) 2005-03-31
EP1450816A4 (en) 2008-02-13

Similar Documents

Publication Publication Date Title
TW200300078A (en) Method of treating disorder related to high cholesterol concentration
US20100093687A1 (en) Method Of Treating Disorder Related To High Cholesterol Concentration
ES2296928T3 (es) Receptores x hepaticos.
TW200306801A (en) Farnesoid X-activated receptor agonists
FR2651677A1 (fr) Composition pharmaceutique a base de salmeterol et du propionate de fluticasone.
CA2274779A1 (en) Aminosterol ester compounds
JP2009533457A (ja) C−ニトロソから誘導されるニトロキシル供与体
JP2930245B2 (ja) 1,2,3,4―テトラヒドロ―9―アクリジナミンの誘導体
US7078396B2 (en) Method of treating disorder related to high cholesterol concentration
WO2012027727A2 (en) Lipomacrocycles and uses thereof
WO2016141458A1 (en) Bisphenol ether derivatives and methods for using the same
JP2002500616A (ja) 神経学的に活性なアミノステロイド
JP2002518514A (ja) テストステロン誘導体
ES2286042T3 (es) 18-nor-esteroides como estrogenos eficaces selectivamente.
JPH01197438A (ja) 更年期障害およびホルモン依存性腫瘍の治療用ならびに避妊薬として使用するための医薬調剤およびその製法
JPH0770013A (ja) β3 −アドレナリン作動薬として作用する{(7S)−7−[(2R)−2−(3−クロロフェニル)−2−ヒドロキシエチルアミノ]−5,6,7,8−テトラヒドロナフタレン−2−イルオキシ)酢酸及びその薬学的に許容されうる塩、並びにそれらが存在する薬学的組成物及び研究室用試薬
TWI286140B (en) 9-alpha-substituted estratrienes as selectively active estrogens
CN101218245B (zh) 炔雌醇的3-酯前药
JPH0640914A (ja) フィソスチグミンの新誘導体、それらの用途及びそれらを含む製薬組成物
JPH09510735A (ja) スピロスタニルグリコシド性結晶
TW200911824A (en) 8-beta-substituted estratrienes as selectively active estrogens
JP2000503985A (ja) 増強剤としての新規なステロイドカルバメート
EP0470995A1 (en) USE OF STEROIDS AS AN ANTI-FUNGI AGENT.
AU2002356919B2 (en) Method of treating disorder related to high cholesterol concentration
CN101284795B (zh) 一类非甾体雄激素受体调节剂及其医学用途